Wilson Therapeutics is a biopharmaceutical company, based in

Stockholm Stockholm () is the Capital city, capital and List of urban areas in Sweden by population, largest city of Sweden as well as the List of urban areas in the Nordic countries, largest urban area in Scandinavia. Approximately 980,000 people liv ...

Sweden Sweden, formally the Kingdom of Sweden,The United Nations Group of Experts on Geographical Names states that the country's formal name is the Kingdom of SwedenUNGEGN World Geographical Names, Sweden./ref> is a Nordic country located on ...

, that develops novel therapies for rare diseases. The company is listed in the Mid-Cap segment on Nasdaq Stockholm with the stock ticker WTX. Wilson Therapeutics' lead product, Decuprate, is the proprietary bis-choline salt of tetrathiomolybdate. Decuprate is initially being developed as a novel treatment for

Wilson's disease Wilson's disease is a genetic disorder in which excess copper builds up in the body. Symptoms are typically related to the brain and liver. Liver-related symptoms include vomiting, weakness, fluid build up in the abdomen, swelling of the legs, ...

, a rare

genetic disease A genetic disorder is a health problem caused by one or more abnormalities in the genome. It can be caused by a mutation in a single gene (monogenic) or multiple genes (polygenic) or by a chromosomal abnormality. Although polygenic disorders ...

that affects approximately 1 in 30,000, causing copper overload in the liver, brain and other tissues and resulting in organ damage and dysfunction. Decuprate has been granted

orphan drug An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases. The assignment of ...

designation for the treatment of Wilson's disease in both Europe and the United States. Wilson Therapeutics presented during the 10th Kempen & Co Life Sciences Conference 2017 and showed the world the result with the drug Decuprate. The company also presented during the international investmentconference Bioequity Europe in Paris, France, on May 23, 2017, and showed some promising result.

Clinical trials

As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in

oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...

and Wilson's disease, as well as some other clinical pathologies.

History

Wilson Therapeutics was founded in 2012 by

HealthCap HealthCap is a specialized provider of venture capital within life sciences. HealthCap invests in innovative companies with focus on therapeutics. As of 2017, HealthCap has invested in over 100 companies since inception and completed initial public ...

, one of the leading European life science venture capital funds. In 2014, Wilson Therapeutics closed a $40 million Series B financing co-led by new investors, Abingworth LLP, MVM Life Science Partners LLP and NeoMed Management AS. HealthCap also participated in the round. On April 29, 2016, Wilson Therapeutics announced its initial public offering on

Nasdaq Stockholm Nasdaq Stockholm, formerly known as the Stockholm Stock Exchange ( sv, Stockholmsbörsen), is a stock exchange located in Frihamnen, Stockholm, Sweden. Founded in 1863, it has become the primary securities exchange of the Nordic countries. As o ...

and had its first day of trading on May 12, 2016.http://www.nasdaqomx.com/newsroom/pressreleases/pressrelease?messageId=1459074&displayLanguage=en

References

{{Reflist, 35em Pharmaceutical companies of Sweden Orphan drug companies 2018 mergers and acquisitions Pharmaceutical companies established in 2012 Swedish companies established in 2012 Companies based in Stockholm